The ALKBH5 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa cell line and designed to ablate expression of the human ALKBH5 gene. This polyclonal knockout product provides a heterogeneous pool of cells harboring targeted disruption of the ALKBH5 locus, enabling loss-of-function studies without clonal selection. The resulting model is suitable for investigating the functional roles of ALKBH5 in RNA modification, gene regulation, and cancer biology.
The host cell line, HeLa, is an immortalized human cervical adenocarcinoma line harboring integrated human papillomavirus type 18 (HPV-18) sequences. It is one of the most widely employed cancer models in biomedical research, characterized by robust growth in culture and extensive molecular characterization. The cells retain an epithelial morphology and serve as a paradigm for studying HPV-driven carcinogenesis and general cancer cell biology.
ALKBH5 encodes an RNA N6-methyladenosine (m6A) demethylase that catalyzes oxidative removal of methyl groups from m6A residues on nascent mRNAs, thereby opposing the methyltransferase activity of the METTL3/METTL14 complex. Within the m6A regulatory network, ALKBH5 functions downstream of transcription factors such as HIF1A and SP1, and is post-transcriptionally modulated by miR-193a-3p. Its enzymatic activity directly modulates the stability and splicing of target transcripts including FOXM1, NANOG, SOX2, and MYC, as well as spliceosomal RNAs. ALKBH5 interacts with splicing regulators SRSF1 and SRSF2, the spliceosome component U2AF2, and RNA processing factors DDX3 and DGCR8. This demethylase is integrated into a broader epitranscriptomic machinery that includes the reader proteins YTHDF1/2/3 and IGF2BP1/2/3, which decode m6A marks to influence mRNA fate.
In the HeLa cervical cancer model, ALKBH5-mediated m6A demethylation is critical for controlling gene expression programs associated with proliferation and epithelial-mesenchymal transition (EMT). Disruption of ALKBH5 leads to hypermethylation of its target transcripts, resulting in altered mRNA processing and reduced expression of key oncogenic factors, thereby impairing tumorigenic properties. Given that ALKBH5 is implicated in hypoxia response and EMT, this knockout model is particularly relevant for dissecting the epitranscriptomic contributions to cervical cancer progression and for evaluating therapeutic strategies that target RNA modification pathways.
This polyclonal knockout cell pool is ideally suited for a wide range of applications in m6A epitranscriptomics, including MeRIP-seq to map m6A landscapes, RNA-seq to assess transcriptome-wide changes, and functional studies employing migration and invasion assays. Additional assays such as RT-qPCR and western blotting enable validation of ALKBH5 ablation, while cell viability and drug response assays provide a platform for testing compounds that modulate m6A metabolism. For further information and to request product details, please contact Ascent Research.
